Thursday, 16 August 2018

Lupin’s Pithampur Unit gets clearence by Health Canada

02 April 2018 | News

Following the review, Health Canada has maintained the compliant rating for Unit 2 at Pithampur (Indore) and has issued a revised ‘Establishment License’

Pharma major Lupin Limited (Lupin) has announced the successful facility review carried out by Health Canada for its Pithampur Unit 2 (Indore) manufacturing facility.

Following the review, Health Canada has maintained the compliant rating for Unit 2 at Pithampur (Indore) and has issued a revised ‘Establishment License’.

Commenting on the development, Nilesh Gupta, Managing Director, Lupin said: “Lupin is committed to maintaining truly global quality standards at our manufacturing units. The successful review by Health Canada is a significant milestone in that journey for Pithampur Unit 2 (Indore).”

For the financial year ended 31st March, 2017, Lupin’s consolidated sales and Net profit stood at Rs. 171,198 million (USD 2.55 billion) and Rs. 25,575 million (USD 381 million) respectively.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account





Survey Box

Will government's drug price caps trigger showdown with US?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls